(lp0
S'SciClone Pharmaceuticals Inc.  Moves Higher on Volume Spike for March 22 Equities.com - 8 hours ago SciClone Pharmaceuticals Inc.  traded on unusually high volume on Mar. 22, as the stock gained 1.06% to close at $9.50.SciClone Pharmaceuticals, Inc.  Pressured Under Trend Lines - Midway MonitorThe State Board of Administration of Florida Retirement System Boosts Stake in ... - Petro Global News 24'
p1
aS'Stonepine Capital Management, LLC Buys Recro Pharma, SciClone Pharmaceuticals ... Nasdaq - 15 hours ago Stonepine Capital Management, LLC initiated holdings in SciClone Pharmaceuticals Inc. The purchase prices were between $8.65 and $10.8, with an estimated average price of $10.'
p2
aS'SciClone Pharmaceuticals: Beyond The Death Of A Sales Process Seeking Alpha - Feb 2, 2017 SciClone Pharmaceuticals  is a revenue-generating pharmaceutical company with a portfolio of HBV/HCV, oncology, anti-infection and cardiovascular drug candidates.'
p3
aS'SciClone Pharmaceuticals Inc.  Plunges 5.29% on March 21 Equities.com - Mar 21, 2017 SciClone Pharmaceuticals Inc.  had a rough trading day for Tuesday March 21 as shares tumbled 5.29%, or a loss of $-0.525 per share, to close at $9.40.'
p4
aS"Why SciClone Pharmaceuticals, Inc. Is Surging Higher Motley Fool - Mar 12, 2015 Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis."
p5
aS'SciClone Confirms Receipt Of Unsolicited Proposal From GL Capital And ABG ... PR Newswire  - Nov 14, 2016 FOSTER CITY, Calif., Nov. 14, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc.   today confirmed that it has received an unsolicited, nonbinding proposal from a consortium led by GL Capital Management GP Limited and&nbsp;...'
p6
aS"Why SciClone Pharmaceuticals Is Soaring Today Motley Fool - Nov 10, 2015 So what: SciClone Pharmaceuticals' Zadaxin is an immune stimulating drug that is used to treat hepatitis B. The drug, which isn't available in the United States, is sold primarily in China, which is home to roughly one third of the globe's hepatitis B ..."
p7
aS"SciClone Announces Progress In Advancing Clinical Pipeline For China ... PR Newswire  - Sep 26, 2016 26, 2016 /PRNewswire/ -- SciClone Pharmaceuticals, Inc.  today announced two important achievements in advancing the Company's clinical pipeline and development portfolio in Greater China."
p8
aS'Trading Focus: Checking ATR Levels for SciClone Pharmaceuticals Inc  Baxter Review - 15 hours ago Traders may be narrowing in on the ATR or Average True Range indicator when reviewing technicals. At the time of writing, SciClone Pharmaceuticals Inc  has a 14-day ATR of 0.28. The average true range indicator was created by J. Welles Wilder in&nbsp;...'
p9
aS"Did SciClone Pharmaceuticals Inc  Create Value For Shareholders Over The ... Simply Wall St - Mar 6, 2017 SciClone Pharmaceuticals Inc  delivered a 19.7% ROE over the past year; however, the figure is only significant when we compare it to returns from assets with similar risk profile: the industry average, which stood at 27.38% in the same ...SciClone Pharmaceuticals'  CEO Friedhelm Blobel on Q4 2016 Results ... - Seeking AlphaSciClone Reports 2016 Financial Results And 2017 Outlook - PR Newswire "
p10
a.